Table 1.
Demographic and clinical characteristics of patients (n = 132).
| Characteristic | Value | |
|---|---|---|
| Age (years) | 71.0 (61.8–79.0) | |
| Gender (male/female) | 86/46 | |
| Body weight (kg) | 73.5 (65.0–89.0) | |
| BMI (kg/m2) | 25.7 (22.5–30.1) | |
| Serum creatinine (mg/dL) | 0.90 (0.68–1.36) | |
| eGFR (mL/min/1.73 m2) | 83.7 (50.5–101.7) | |
| Serum albumin (g/L) | 3.1 (2.7–3.4) | |
| Type of infection, n (%) | ||
| Hospital-acquired pneumonia | 38 (28.8) | |
| Endocarditis | 27 (20.5) | |
| Bloodstream infection | 22 (16.6) | |
| Community-acquired pneumonia | 20 (15.2) | |
| Bone and joint infections | 9 (6.8) | |
| Skin and soft tissue infections | 9 (6.8) | |
| Device-related infections | 4 (3.0) | |
| CNS infections | 3 (2.3) | |
| Patients with identified microbiological isolates, n (%) | 80 (60.6) | |
| Ceftobiprole treatment | ||
| Median dose (mg daily) | 1500 (1000–1500) | |
| Trough concentration (mg/L) | 7.6 (4.9–11.7) | |
| Length of treatment (days) | 10.0 (2.0–81.0) | |
| Patients with co-administered antibiotics, n (%) | 88 (66.7) | |
| Treatment outcome in assessable patients (n = 126) | ||
| N. of patients with microbiological eradication | 118 (96.7) | |
| N. of patients with clinical cure | 88 (69.8) | |
Data are presented as median (IQR) for continuous variables and as number (%) for dichotomous variables. BMI, body mass index; CNS, central nervous system; eGFR, estimated glomerular filtration rate.